Legend Biotech reported net trade sales of $439 million for CARVYKTI® with positive long-term outcomes in the CARTITUDE-1 study. Over 7,500 patients have been treated to date. Cash and cash equivalents total $1.0 billion as of June 30, 2025. The FDA removed REMS for approved CAR T cell therapies, including CARVYKTI, and updated product labeling. Legend Biotech aims for profitability in 2026 with a strong financial position. At ASCO, important CARVYKTI® and solid tumor data was presented. The company is focused on delivering innovative cell therapy solutions worldwide, with over 2,800 employees. Regulatory updates include the removal of REMS for approved CAR T cell therapies, including CARVYKTI. Legend Biotech aims for profitability in 2026 and presented key business developments at ASCO. Financially, the company reported $1.0 billion in cash and cash equivalents as of June 30, 2025. The second quarter 2025 financial results show promising growth and progress for Legend Biotech. Adjusted Net Income (Loss) and ANI per Share were used as performance metrics to enhance investor understanding of financial performance. Adjusted Net Income (Loss) excludes certain items not representative of the core business. A reconciliation between Adjusted Net Income (Loss) and Net Loss was provided for transparency.

Read more at GlobeNewswire: Legend Biotech Reports Second Quarter 2025 Results and